This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (147)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Aging/ Geriatrics  • Cardiovascular System  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic  Social Bookmarking   What's this?

Muhammad Mamdani, PharmD, MA, MPH; Paula Rochon, MD, MPH; David N. Juurlink, MD; Geoffrey M. Anderson, MD, PhD; Alex Kopp, BA; Gary Naglie, MD; Peter C. Austin, PhD; Andreas Laupacis, MD, MSc

Arch Intern Med. 2003;163:481-486.

Background  Recent debate has emerged regarding the cardiovascular safety of selective cyclooxygenase 2 inhibitors and the possible cardioprotective effect of naproxen sodium. We compared the rates of acute myocardial infarction (AMI) among elderly patients dispensed selective cyclooxygenase 2 inhibitors, naproxen, and nonselective nonnaproxen nonsteroidal anti-inflammatory drugs (NSAIDs).

Methods  We conducted a population-based retrospective cohort study using administrative health care data from Ontario, Canada, from April 1, 1998, to March 31, 2001. We identified NSAID-naive cohorts of subjects aged 66 years and older in whom treatment was initiated with celecoxib (n = 15 271), rofecoxib (n = 12 156), naproxen (n = 5669), and nonnaproxen nonselective NSAIDs (n = 33 868), along with a randomly selected control cohort not exposed to NSAIDs (n = 100 000). Multivariate Cox proportional hazards models were used to compare AMI rates between study drug groups while controlling for potential confounders.

Results  Relative to control subjects, the multivariate model showed no significant differences in AMI risk for new users of celecoxib (adjusted rate ratio [aRR], 0.9; 95% confidence interval [CI], 0.7-1.2), rofecoxib (aRR, 1.0; 95% CI, 0.8-1.4), naproxen (aRR, 1.0; 95% CI, 0.6-1.7), or nonnaproxen nonselective NSAIDs (aRR, 1.2; 95% CI, 0.9-1.4).

Conclusions  The findings of this observational study suggest no increase in the short-term risk of AMI among users of selective cyclooxygenase 2 inhibitors as commonly used in clinical practice. Furthermore, the findings do not support a short-term reduced risk of AMI with naproxen.

From the Institute for Clinical Evaluative Sciences (Drs Mamdani, Rochon, Juurlink, Anderson, Naglie, Austin, and Laupacis and Mr Kopp); Faculty of Pharmacy (Dr Mamdani) and the Departments of Medicine (Drs Rochon, Juurlink, Naglie, and Laupacis), Health Policy, Management, and Evaluation (Dr Anderson), and Public Health Sciences (Dr Austin), Faculty of Medicine, University of Toronto; Division of General Internal Medicine, Sunnybrook and Women's College Health Sciences Centre (Drs Juurlink and Laupacis); Department of Geriatric Medicine, University Health Network and Toronto Rehabilitation Institute (Dr Naglie); and Department of Geriatric Medicine, Baycrest Centre for Geriatric Care (Dr Rochon), Toronto, Ontario. In the past 2 years, Dr Mamdani has conducted research in an unrelated content area at the request of an academic institution whose funding was supported by Pharmacia Corporation (Peapack, NJ), but none of the funding for this study was provided by any pharmaceutical company.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study
Juurlink et al.
BMJ 2009;339:b2942-b2942.
ABSTRACT | FULL TEXT  

A population-based study of the drug interaction between proton pump inhibitors and clopidogrel
Juurlink et al.
CMAJ 2009;180:713-718.
ABSTRACT | FULL TEXT  

Statistical methods in pharmacoepidemiology: advances and challenges
Suissa
Stat Methods Med Res 2009;18:3-6.
 

The Risk of Acute Myocardial Infarction with Etodolac Is not Increased Compared to Naproxen: A Historical Cohort Analysis of a Generic COX-2 Selective Inhibitor
Warner et al.
J CARDIOVASC PHARMACOL THER 2008;13:252-260.
ABSTRACT  

Cyclooxygenase Selectivity of Nonsteroidal Anti-inflammatory Drugs and Risk of Stroke
Haag et al.
Arch Intern Med 2008;168:1219-1224.
ABSTRACT | FULL TEXT  

Editorial: On the selective inhibitors of Cyclooxygenase-2: Do we have a last word?
Ferrario
Ther Adv Cardiovasc Dis 2008;2:75-78.
 

Cyclooxygenase-2 Inhibitors and Most Traditional Nonsteroidal Anti-inflammatory Drugs Cause Similar Moderately Increased Risks of Cardiovascular Disease
Hennekens and Borzak
J CARDIOVASC PHARMACOL THER 2008;13:41-50.
ABSTRACT  

Immortal Time Bias in Pharmacoepidemiology
Suissa
Am J Epidemiol 2008;167:492-499.
ABSTRACT | FULL TEXT  

Cardiovascular Thromboembolic Adverse Effects Associated with Cyclooxygenase-2 Selective Inhibitors and Nonselective Antiinflammatory Drugs
Joshi et al.
Anesth. Analg. 2007;105:1793-1804.
ABSTRACT | FULL TEXT  

Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials
Scott et al.
Ann Rheum Dis 2007;66:1296-1304.
ABSTRACT | FULL TEXT  

Rofecoxib and Cardiovascular Adverse Events in Adjuvant Treatment of Colorectal Cancer
Kerr et al.
NEJM 2007;357:360-369.
ABSTRACT | FULL TEXT  

Nonselective Nonsteroidal Antiinflammatory Drugs and Cardiovascular Risk: Are They Safe?
Waksman et al.
The Annals of Pharmacotherapy 2007;41:1163-1173.
ABSTRACT | FULL TEXT  

The Cycloxygenase 2 (COX-2) Story: It's Time to Explain, Not Inflame
Salinas et al.
J CARDIOVASC PHARMACOL THER 2007;12:98-111.
ABSTRACT  

An Evidence-Based Update on Nonsteroidal Anti-Inflammatory Drugs
Ong et al.
Clin Med Res 2007;5:19-34.
ABSTRACT | FULL TEXT  

Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study
Rahme and Nedjar
Rheumatology (Oxford) 2007;46:435-438.
ABSTRACT | FULL TEXT  

Coxibs and Heart Disease: What We Have Learned and What Else We Need to Know
Zarraga and Schwarz
J Am Coll Cardiol 2007;49:1-14.
ABSTRACT | FULL TEXT  

Non-steroidal anti-inflammatory drugs--changes in prescribing may be warranted
Madhok et al.
Rheumatology (Oxford) 2006;45:1458-1460.
FULL TEXT  

Cardiovascular Risk and Inhibition of Cyclooxygenase: A Systematic Review of the Observational Studies of Selective and Nonselective Inhibitors of Cyclooxygenase 2
McGettigan and Henry
JAMA 2006;296:1633-1644.
ABSTRACT | FULL TEXT  

Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs.
Chaiamnuay et al.
Am J Health Syst Pharm 2006;63:1837-1851.
ABSTRACT | FULL TEXT  

Use of Non-Aspirin Nonsteroidal Antiinflammatory Drugs and the Risk of Cardiovascular Events
Cheng
The Annals of Pharmacotherapy 2006;40:1785-1796.
ABSTRACT | FULL TEXT  

Using Pharmacoepidemiology To Inform Drug Coverage Policy: Initial Lessons From A Two-Province Collaborative
Paterson et al.
Health Aff (Millwood) 2006;25:1436-1443.
ABSTRACT | FULL TEXT  

NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland
Helin-Salmivaara et al.
Eur Heart J 2006;27:1657-1663.
ABSTRACT | FULL TEXT  

What Price Pain Relief?
Hochman and Shah
Circulation 2006;113:2868-2870.
FULL TEXT  

Coxibs Versus Combination NSAID and PPI Therapy for Chronic Pain: An Exploration of the Risks, Benefits, and Costs
Hur et al.
The Annals of Pharmacotherapy 2006;40:1052-1063.
ABSTRACT | FULL TEXT  

Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors
Levesque et al.
CMAJ 2006;174:1563-1569.
ABSTRACT | FULL TEXT  

Use of First- and Second-Generation Cyclooxygenase-2-Selective Nonsteroidal Antiinflammatory Drugs and Risk of Acute Myocardial Infarction
Andersohn et al.
Circulation 2006;113:1950-1957.
ABSTRACT | FULL TEXT  

Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and the Risk of Cardiovascular Events
Chan et al.
Circulation 2006;113:1578-1587.
ABSTRACT | FULL TEXT  

Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis.
Caldwell et al.
JRSM 2006;99:132-140.
ABSTRACT | FULL TEXT  

Can Natriuretic Peptide Levels Predict the Cardiovascular Complications of COX-2 Inhibitors and Nonsteroidal Anti-inflammatory Drugs?
Blankfield
J Am Board Fam Med 2006;19:178-182.
ABSTRACT | FULL TEXT  

Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies
Papanikolaou et al.
CMAJ 2006;174:635-641.
ABSTRACT | FULL TEXT  

Challenges and Opportunities for Pharmacoepidemiology in Drug-Therapy Decision Making
Etminan et al.
J Clin Pharmacol 2006;46:6-9.
ABSTRACT | FULL TEXT  

Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs
Bolten
Ann Rheum Dis 2006;65:7-13.
ABSTRACT | FULL TEXT  

Cardiovascular Complications of Non-Steroidal Anti-Inflammatory Drugs
Fosslien
Annals of Clinical & Laboratory Science 2005;35:347-385.
ABSTRACT | FULL TEXT  

Relative Thromboembolic Risks Associated with COX-2 Inhibitors
Jones
The Annals of Pharmacotherapy 2005;39:1249-1259.
ABSTRACT | FULL TEXT  

Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis
Hippisley-Cox and Coupland
BMJ 2005;330:1366.
ABSTRACT | FULL TEXT  

Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study
Hudson et al.
BMJ 2005;330:1370.
ABSTRACT | FULL TEXT  

Impact of Nonsteroidal Antiinflammatory Drugs on the Cardioprotective Effects of Aspirin
Corman et al.
The Annals of Pharmacotherapy 2005;39:1073-1079.
ABSTRACT | FULL TEXT  

Risk of Hospitalization for Myocardial Infarction Among Users of Rofecoxib, Celecoxib, and Other NSAIDs: A Population-Based Case-Control Study
Johnsen et al.
Arch Intern Med 2005;165:978-984.
ABSTRACT | FULL TEXT  

Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects
Capone et al.
J Am Coll Cardiol 2005;45:1295-1301.
ABSTRACT | FULL TEXT  

The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors: A Population Study of Elderly Adults
Levesque et al.
ANN INTERN MED 2005;142:481-489.
ABSTRACT | FULL TEXT  

Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon et al.
NEJM 2005;352:1071-1080.
ABSTRACT | FULL TEXT  

Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier et al.
NEJM 2005;352:1092-1102.
ABSTRACT | FULL TEXT  

Patients Exposed to Rofecoxib and Celecoxib Have Different Odds of Nonfatal Myocardial Infarction
Kimmel et al.
ANN INTERN MED 2005;142:157-164.
ABSTRACT | FULL TEXT  

Cardiovascular Risks of Cyclooxygenase-2 Inhibitors: Where We Stand Now
Finckh and Aronson
ANN INTERN MED 2005;142:212-214.
FULL TEXT  

Selective Cyclooxygenase-2 Inhibition and Cardiovascular Effects: An Observational Study of a Medicaid Population
Shaya et al.
Arch Intern Med 2005;165:181-186.
ABSTRACT | FULL TEXT  

Rofecoxib, Merck, and the FDA
Kim et al.
NEJM 2004;351:2875-2878.
FULL TEXT  

Impact of Prolonged Cyclooxygenase-2 Inhibition on Inflammatory Markers and Endothelial Function in Patients With Ischemic Heart Disease and Raised C-Reactive Protein: A Randomized Placebo-Controlled Study
Bogaty et al.
Circulation 2004;110:934-939.
ABSTRACT | FULL TEXT  

Nonsteroidal Antiinflammatory Drugs and the Risk of Myocardial Infarction in the General Population
Garcia Rodriguez et al.
Circulation 2004;109:3000-3006.
ABSTRACT | FULL TEXT  

Colorectal Adenomas: A Prototype for the Use of Surrogate End Points in the Development of Cancer Prevention Drugs
Kelloff et al.
Clin. Cancer Res. 2004;10:3908-3918.
FULL TEXT  

Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults
Solomon et al.
Circulation 2004;109:2068-2073.
ABSTRACT | FULL TEXT  

Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic
WARNER and MITCHELL
FASEB J. 2004;18:790-804.
ABSTRACT | FULL TEXT  

Clinical Pharmacology of Platelet, Monocyte, and Vascular Cyclooxygenase Inhibition by Naproxen and Low-Dose Aspirin in Healthy Subjects
Capone et al.
Circulation 2004;109:1468-1471.
ABSTRACT | FULL TEXT  

Nonsteroidal Anti-Inflammatory drugs and cardiovascular risk
Howard and Delafontaine
J Am Coll Cardiol 2004;43:519-525.
ABSTRACT | FULL TEXT  

Coxibs and the endothelium
Verma and Szmitko
J Am Coll Cardiol 2003;42:1754-1756.
FULL TEXT  

Inhibition of Clinical Benefits of Aspirin on First Myocardial Infarction by Nonsteroidal Antiinflammatory Drugs
Kurth et al.
Circulation 2003;108:1191-1195.
ABSTRACT | FULL TEXT  

MI Risk with COX-2 Inhibitors vs. Naproxen in the Elderly
Journal Watch Cardiology 2003;2003:6-6.
FULL TEXT  

No Increase in MI Risk with Rofecoxib ... And No Decrease with Naproxen
JWatch General 2003;2003:1-1.
FULL TEXT  

The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors: A Population Study of Elderly Adults
Levesque et al.
ANN INTERN MED 2005;142:481-489.
ABSTRACT | FULL TEXT